Posters

Topical 0.05% cyclosporine A eyedrops in the treatment of moderate–severe vernal keratoconjunctivitis

Poster Details

First Author: T. Ayyildiz TURKEY

Co Author(s):    K. Calisir   U. Calli                 

Abstract Details

Purpose:

To investigate the efficacy of topical cyclosporine A (CsA) 0.05% in patients with moderate-to-severe vernal keratoconjunctivitis (VKC).

Setting:

Retrospective cohort, observational study

Methods:

This retrospective study included 37 patients who were admitted to our clinic between January 2015 to December 2015. All patients were diagnosed with moderate-to-severe VKC and had topical CsA 0.05% (Restasis Allergan, Inc. Irvine, USA) treatment. VKC diagnosis was based on patient history and typical clinical signs and symptoms. Sign and symptom scores of each patient were obtained at pre-treatment and during treatment (1, 3 and 6. months).

Results:

Of the 37 patients, 20 (54.1%) were male and 17 (45.9%) were female. The mean age of the patients was 11.83±4.70 year (6-24 year). The symptom-sign scores and total scores of the patients were significantly reduced at 1, 3 and 6 month time points when compared to baseline values. Symptom-sign scores were also significantly reduced from 1 month to 3 month and from 3 month to 6 month (p<0.05).

Conclusions:

Topical CsA 0.05% is an effective formulation that is used in the treatment of moderate-to-severe VK patients and it may reduce need for steroids.

Financial Disclosure:

NONE